PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?
Copyright © 2021 Menniti, Chappie and Schmidt..
PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in striatal medium spiny neurons. These neurons dynamically integrate cortical information with dopamine-signaled value to mediate action selection among available behavioral options. Medium spiny neurons are components of either the direct or indirect striatal output pathways. Selective activation of indirect pathway medium spiny neurons by dopamine D2 receptor antagonists is putatively a key element in the mechanism of their antipsychotic efficacy. While PDE10A is expressed in all medium spiny neurons, studies in rodents indicated that PDE10A inhibition has behavioral effects in several key assays that phenocopy dopamine D2 receptor inhibition. This finding gave rise to the hypothesis that PDE10A inhibition also preferentially activates indirect pathway medium spiny neurons, a hypothesis that is consistent with electrophysiological, neurochemical, and molecular effects of PDE10A inhibitors. These data underwrote industry-wide efforts to investigate and develop PDE10A inhibitors as novel antipsychotics. Disappointingly, PDE10A inhibitors from 3 companies failed to evidence antipsychotic activity in patients with schizophrenia to the same extent as standard-of-care D2 antagonists. Given the notable similarities between PDE10A inhibitors and D2 antagonists, gaining an understanding of why only the latter class is antipsychotic affords a unique window into the basis for this therapeutic efficacy. With this in mind, we review the data on PDE10A inhibition as a step toward back-translating the limited antipsychotic efficacy of PDE10A inhibitors, hopefully to inform new efforts to develop better therapeutics to treat psychosis and schizophrenia.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Frontiers in neuroscience - 14(2020) vom: 25., Seite 600178 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Menniti, Frank S [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antipsychotic action |
---|
Anmerkungen: |
Date Revised 10.02.2021 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3389/fnins.2020.600178 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM32112247X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM32112247X | ||
003 | DE-627 | ||
005 | 20231225175136.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3389/fnins.2020.600178 |2 doi | |
028 | 5 | 2 | |a pubmed24n1070.xml |
035 | |a (DE-627)NLM32112247X | ||
035 | |a (NLM)33551724 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Menniti, Frank S |e verfasserin |4 aut | |
245 | 1 | 0 | |a PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action? |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 10.02.2021 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright © 2021 Menniti, Chappie and Schmidt. | ||
520 | |a PDE10A, a phosphodiesterase that inactivates both cAMP and cGMP, is a unique signaling molecule in being highly and nearly exclusively expressed in striatal medium spiny neurons. These neurons dynamically integrate cortical information with dopamine-signaled value to mediate action selection among available behavioral options. Medium spiny neurons are components of either the direct or indirect striatal output pathways. Selective activation of indirect pathway medium spiny neurons by dopamine D2 receptor antagonists is putatively a key element in the mechanism of their antipsychotic efficacy. While PDE10A is expressed in all medium spiny neurons, studies in rodents indicated that PDE10A inhibition has behavioral effects in several key assays that phenocopy dopamine D2 receptor inhibition. This finding gave rise to the hypothesis that PDE10A inhibition also preferentially activates indirect pathway medium spiny neurons, a hypothesis that is consistent with electrophysiological, neurochemical, and molecular effects of PDE10A inhibitors. These data underwrote industry-wide efforts to investigate and develop PDE10A inhibitors as novel antipsychotics. Disappointingly, PDE10A inhibitors from 3 companies failed to evidence antipsychotic activity in patients with schizophrenia to the same extent as standard-of-care D2 antagonists. Given the notable similarities between PDE10A inhibitors and D2 antagonists, gaining an understanding of why only the latter class is antipsychotic affords a unique window into the basis for this therapeutic efficacy. With this in mind, we review the data on PDE10A inhibition as a step toward back-translating the limited antipsychotic efficacy of PDE10A inhibitors, hopefully to inform new efforts to develop better therapeutics to treat psychosis and schizophrenia | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a PDE10A | |
650 | 4 | |a antipsychotic action | |
650 | 4 | |a basal ganglia | |
650 | 4 | |a cyclic nucleotide phosphodiesterase | |
650 | 4 | |a dopamine | |
650 | 4 | |a medium spiny neuron | |
650 | 4 | |a schizophrenia | |
700 | 1 | |a Chappie, Thomas A |e verfasserin |4 aut | |
700 | 1 | |a Schmidt, Christopher J |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Frontiers in neuroscience |d 2007 |g 14(2020) vom: 25., Seite 600178 |w (DE-627)NLM184194563 |x 1662-4548 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2020 |g day:25 |g pages:600178 |
856 | 4 | 0 | |u http://dx.doi.org/10.3389/fnins.2020.600178 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2020 |b 25 |h 600178 |